Wegovy: a game-changing anti-obesity medication

Wegovy is an injectable medication that was developed by Novo Nordisk, a Danish pharmaceutical company. Semaglutide, the active ingredient in Wegovy, was initially designed as a treatment for type 2 diabetes

Clinical trials have shown that Wegovy can help with weight loss and overall health improvement. In trials, patients with obesity and without diabetes taking Wegovy alongside a fitness and nutrition plan saw upwards of 15% total body weight loss on average—some individuals losing up to 33%.

More research is needed to understand the full benefits of semaglutide and other GLP-1 medications. So far, studies have proposed evidence for GLP-1 medications having multiple positive biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition.